SlideShare ist ein Scribd-Unternehmen logo
1 von 43
Downloaden Sie, um offline zu lesen
Q2 2015 RESULTS
July 30, 2015
2
Forward Looking Statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events, operations, services, product development and potential,
and statements regarding future performance. Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which
are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to
differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the
EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such
product candidates as well as their decisions regarding labeling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will
be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability
to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form
20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements.
KEY HIGHLIGHTS
3
Olivier Brandicourt
Chief Executive Officer
Q2 2015 - A Solid Quarterly Performance
4
Delivering
mid-single digit sales
growth
Posting
solid financial results
Bringing
innovative medicines
to market
GBUs: Global Business Units
(1) On a reported basis, Q2 2015 sales were up +16.1%
(2) On a reported basis, Q2 2015 Business EPS was up +20.5%
(3) FDA submissions of lixisenatide, LixiLan and sarilumab
(4) Effective January 1, 2016
Building
a sustainable
path forward
11
22
33
44
● Higher OpEx driven by investment in new launches
● Business EPS up +5.1% at CER(2)
● Sales up +4.9% at CER(1)
● Sales growth across all geographies and businesses
except Diabetes
● Praluent®: FDA approval and positive CHMP opinion
● Three regulatory filings expected in H2 2015(3)
● New alliance with Regeneron in Immuno-Oncology
● Reorganization around five GBUs recently announced(4)
FX Impact
+€0.18
Incremental
EPS at CER
+€0.06
Q2 2014 Q2 2015
Net Sales Business EPS
Solid Sales and Business EPS Delivered in Q2 2015
5
(1) On a reported basis, Q2 2015 sales were up +16.1% and Business EPS was up +20.5%
+5.1%
at CER(1)
FX Impact Q2 2015
+€910m
Incremental
Sales at CER
+€393m
Q2 2014
+4.9%
at CER(1)
€8,075m
€9,378m
€1.17
€1.41
Q2 2015 Sales by Business Areas
(1) Q2 2015 sales were up +4.9% at CER and +16.1% on a reported basis
Growth at CER
Genzyme
Generics
Consumer Healthcare
Diabetes
Oncology
€907m
€520m
€890m
€1,988m
€390m
+26.6%
+9.2%
+1.3%
-3.8%
+3.6%
Sales Growth Delivered Across All Businesses in Q2 2015
Except for Diabetes(1)
% of Sales
9.7%
9.5%
21.2%
5.5%
4.2%
Animal Health
Vaccines
€691m
€887m
+14.2%
+8.6%9.5%
7.4%
Pharmaceuticals €7,800m +3.7%83.1%
6
Established Products €3,105m +3.1%33.0%
Sales Growth
at CER
Q1
2015
Q2
2015
U.S. -12.0% -14.0%
Western EU +4.7% +6.5%
Emerging
Markets
+18.5% +17.0%
RoW -6.0% +4.8%
Worldwide -3.2% -3.8%
Q2 2015 Diabetes Sales Consistent with Previous Quarter
21.2%78.8%
57%
43%
U.S. ex U.S.
Diabetes
Sales
€1,988m
-3.8% at CER
Total Group Sales
excluding Diabetes
€7,390m
+7.3% at CER
Q2 2015 Diabetes Sales by Geographies (in €m)
€854m
+11.2% at CER
€1,134m
-14.0% at CER
Expected launch of insulin glargine biosimilar in Europe(1) and Japan in H2 2015
7
(1) Already launched in two Eastern European markets
0
1 000
2 000
3 000
4 000
5 000
6 000
7 000
Week1
Week2
Week3
Week4
Week5
Week6
Week7
Week8
Week9
Week10
Week11
Week12
Week13
Week14
Week15
Week16
0
10
20
30
40
50
60
70
80
Week1
Week2
Week3
Week4
Week5
Week6
Week7
Week8
Week9
Week10
Week11
Week12
Week13
Week14
Week15
Week16
Basal Market NRx Shares
week of April 3 - week of July 17, 2015
Total glargine
67.1%
Levemir®
25.6%
Share (%)
(2)
(1)
Encouraging U.S. Launch Metrics
and Global Launch Ongoing
(1) Basal market includes Toujeo®, Lantus®, Levemir® (a Novo Nordisk brand) and NPH - Source: IMS Weekly Data
(2) Total glargine includes Toujeo® and Lantus®
(3) Source: IMS Weekly Data 8
Toujeo® Market Access
as of August 1, 2015
% Lives Covered
28%
45%
0%
20%
40%
60%
80%
100%
Commercial Medicare
Tier 2
Tier 2
Tier 3
91%
73%
Toujeo® TRx & NRx Volume
week of April 3 - week of July 17, 2015
NRx
4,507
Cumulative NRx
40,891
Rx (absolute)
Cumulative TRx
51,829
TRx
6,539
(3)
EU launch ongoing and approval in Japan, Canada, Australia recently granted
Rare Disease Franchise Sustained Growth Momentum
and Strengthened Leadership(1)
in Q2 2015
9
Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015
Others
Fabrazyme
Myozyme
Cerdelga
Cerezyme
Genzyme Rare Disease Sales (€m)
€647m
+9.1% at CER
€540m
€146m
€199m
€121m
€165m
(1) Cerezyme® + Cerdelga® value share is 74% and Fabrazyme® value share is 58% based on Q2 2015 reported sales by Sanofi and Shire
(2) Cerdelga® sales were €16m in Q2 2015
(2)
&
Others
Multiple Sclerosis Franchise Sales Now Annualizing(1)
Over €1bn
10
Genzyme Multiple Sclerosis Sales (€m)
Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015
Lemtrada Aubagio
€260m
+118.4% at CER
€103m
€56m
€204m
®
New Global Campaign
(1) Multiplying Q2 2015 sales of €260m by four provides a hypothetical annual run rate of over €1bn sales
* AUBAGIO® (teriflunomide) is effective across
key measures of disease activity: sustained
disability progression (14 mg only), annualized
relapse rate, and MRI activity. Common side
effects with AUBAGIO led to treatment
discontinuation rates ≤3.3% in clinical trials.
A Breakthrough Innovation to Help
Reduce the Burden of Dengue(2)
Vaccines Showed Broad Sales Momentum in Q2 2015
11
Sanofi Pasteur Sales (€m)
Q2 2015
€887m
Q2 2014
€718m
Other
Adult Boosters
Travel/Endemic
Polio/Pertussis/Hib
Influenza Vaccines
Meningitis/Pneumo
(1)
+8.6%
at CER
(1) Includes VaxServe, a U.S. healthcare supplier serving primary care physician offices, community immunization providers,
immunizing pharmacies, travel clinics and corporations
(2) WHO, 2012, Global Strategy for Dengue Prevention and Control
● Regulatory submissions in key
endemic countries in Asia and Latin
America completed in June 2015
● First license anticipated
before year-end 2015
Targeting over 65m doses of flu vaccines to be distributed in the U.S. in 2015
Merial Sales Growth (at CER)
Animal Health Continued its Strong Recovery in Q2 2015
12
Q2
2013
Q3
2013
Q4
2013
Q1
2014
Q2
2014
Q3
2014
Q4
2014
Q1
2015
Q2
2015
-5.7% -6.3%-6.4%
-1.6%
+12.7%
+6.2%
+11.5%
+13.5%
+14.2%
Five consecutive quarters of strong sales growth
NexGard® U.S. Campaign
(1) Merial sales growth excluding NexGard® was +7.8% at CER in Q2 2015
(1)
(1) World excluding U.S., Canada, Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta,
Belgium, Luxembourg, Portugal, the Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway,
Iceland, Denmark), Japan, South Korea, Australia, and New Zealand
(2) RoW: Japan, South Korea, Canada, Australia, and New Zealand
Sales Growth Delivered Across All Geographies in Q2 2015
33.9%
34.7%
21.3%
10.1%
13
(1) €602m €616m
€934m
€982m
Africa & Middle
East
Eastern Europe,
Russia & Turkey
Asia Latin America
+3.0% +9.3% +7.1%Growth at CER +9.0%
Emerging Markets Sales by Region
Emerging
Markets
€3,182m
+7.5% at CER
U.S.
€3,250m
+2.1% at CER
Western EU
€1,998m
+3.4% at CER
RoW
€948m
+8.2% at CER
(2)
Q2 2015 Sales by Geographies (in €m)
14
New Strategic Alliance with Regeneron to Develop
Cancer Treatments in Emerging Field of Immuno-Oncology
● Establish Sanofi’s presence in immuno-oncology,
a rapidly growing and promising approach to treat cancer
 Significant unmet needs remain despite advances shown
with checkpoint inhibitors
● Expand our oncology pipeline, developing best-in-class new
antibodies and novel combination products(1)
 Alliance includes PD-1(2) in Phase I and a portfolio of antibodies,
including LAG3, GITR and PD-L1 currently in Preclinical development(3)
● Accelerate development of multiple drug candidates in a
fast-evolving IO field with a scale and focus beyond our
existing discovery agreement
1
2
Committing
to
Immuno
Oncology
3
PD-1: Programmed death protein 1 LAG-3: Lymphocyte activation gene 3
PD-L1: Programmed death ligand 1 GITR: Glucocorticoid-Induced Tumor-necrosis-factor-Receptor-related protein
IO: Immuno-Oncology
(1) Including bi-specifics antibodies
(2) REGN2810
(3) Subject to opting in
15
Ready to Launch Praluent® (alirocumab)
in the U.S. and EU
Positive CHMP opinion on July 23, 2015(1)
 Indicated in adults with primary hypercholesterolemia
(HeFH and non-familial) or mixed dyslipidaemia,
as an adjunct to diet in patients unable to reach their
LDL-C goals with a maximally-tolerated statin
and patients who are statin intolerant, or for whom
a statin is contraindicated
FDA approval granted on July 24, 2015
 Indicated as adjunct to diet and maximally tolerated
statin therapy for the treatment of adults with
heterozygous familial hypercholesterolemia or
clinical atherosclerotic cardiovascular disease, who
require additional lowering of LDL cholesterol
(LDL-C)
(1) EC regulatory decision expected in late September 2015
75 mg
dose
150 mg
dose
(1) ELIXA evaluated CV outcomes in Type 2 Diabetes patients after Acute Coronary Syndrome during treatment with lixisenatide
(2) LixiLan is a once-daily fixed-ratio combination of insulin glargine and lixisenatide
(3) LixiLan-O evalutates the combination of insulin glargine and lixisenatide in patients insufficiently controlled on OADs. LixiLan-L
focuses on patients not at goal on basal insulin. The ongoing LixiLan-L study will be completed in Q3 2015.
Following an analysis of results from both Phase III studies, LixiLan-O and LixiLan-L, Sanofi will determine the next steps
in the regulatory process. Currently, regulatory submissions are planned for Q4 2015 in the U.S. and Q1 2016 in the EU.
(4) SARIL-RA-TARGET, SARIL-RA-EASY and SARIL-RA-ASCERTAIN
Additional Clinical Milestones and Regulatory Filings
Expected in H2 2015
Key Milestones in H2 2015
16
Type 2 Diabetes
Positive ELIXA study
results supported U.S.
regulatory submission
in late July 2015(1)
Type 2 Diabetes
Positive LixiLan-O top-line
results demonstrated
superiority over insulin
glargine or lixisenatide on
HbA1c reduction(3)
LixiLan-L results expected
in Q3 2015(3)
(2)
Rheumatoid Arthritis
3 Phase III trials recently
met their primary
endpoints(4)
Regulatory submission
expected in late 2015
in the U.S. and Q4 2016
in EU
sarilumablixisenatide
 Diabetes
 Cardiovascular
Diabetes
& Cardio-
vascular
P. Witz
 Rare diseases
 Multiple
Sclerosis
 Oncology
 Immunology
Sanofi
Genzyme
(Specialty Care)
D. Meeker
 CHC
 Established
products
 Generics
General
Medicines
& Emerging
Markets
P. Guenter
Sanofi
Pasteur
(Vaccines)
O. Charmeil
Merial
(Animal Health)
C. Hellmann
 Human
vaccines
 Animal Health
products
 Emerging
markets(1)
&
A New Organizational Model with Five Global Business
Units Is a Necessary Step to Drive Focus and Simplification
17
(1) All pharmaceutical businesses in Emerging markets to report to General Medicine & Emerging Markets GBU
(2) Functions include Research & Development, Industrial Affairs, Finance, Human Resources, Business Development & Strategy, External Affairs,
Information Systems, Medical, Legal, Compliance, Procurement (not an exhaustive list of functions)
(3) The process of legal and social consultation will be followed as required
 Similar to R&D and Industrial Affairs, all functions will be globalized(2)
New organization implemented beginning in January 2016(3)
Sanofi to Host an IR Seminar in Q4 2015
18
● Outlining a roadmap towards 2020
● Sharing the outcome of the ongoing business review
● Presenting further progress of our R&D pipeline
● Offering opportunities to interact with management
Friday November 6th, 2015 from 8:30 to 16:00 in Sanofi HQ - Paris
18
Meet
Management
FINANCIAL RESULTS
Jérôme Contamine
Executive Vice President, Chief Financial Officer
19
Net Sales(1)
Business EPS
20
Sustained U.S. Dollar Strength Led to Strong FX Tailwind
on Top and Bottom Line Again in Q2 2015
(1) Main currency impact on sales in Q2 2015: U.S. Dollar (+€645m); Chinese Yuan (+€99m); Brazilian Real (-€33m);
Russian Ruble (-€31m)
Quarterly Currency Impact
-6.2%
-€497m
-5.5%
-€443m
-1.0%
-€81m
+9.9%
+€782m
Q1 2015
Q1 2014 Q2 2014 Q3 2014
Q4 2014
+2.7%
+€229m
Q1 2015
Q1 2014 Q2 2014 Q3 2014
Q4 2014
-9.1%
-€0.11
-8.9%
-€0.10
-€0.03
-2.2%
+1.5%
+€0.02
+10.2%
+€0.12
Q2 2015 Q2 2015
+11.2%
+€910m
+15.4%
+€0.18
CER: Constant Exchange Rates
21
Business Operating Income Up +4.7% at CER
Despite OpEx Increase of +3.7% at CER in Q2 2015
€m Q2 2015 Q2 2014
% Change
(reported €)
% Change
(CER)
Net sales 9,378 8,075 +16.1% +4.9%
Other revenues 83 71 +16.9% +0.0%
Cost of sales (2,938) (2,608) +12.7% +4.8%
Gross profit 6,523 5,538 +17.8% +4.8%
R&D (1,290) (1,188) +8.6% -0.3%
SG&A (2,648) (2,255) +17.4% +5.9%
Other current operating income & expenses (20) 54 - -
Share of Profit/Loss of associates 30 26 - -
Minority interests (29) (30) - -
Business operating income 2,566 2,145 +19.6% +4.7%
Business operating margin 27.4% 26.6% - -
22
€m Q2 2015 Q2 2014
% Change
(reported €)
% Change
(CER)
Business operating income 2,566 2,145 +19.6% +4.7%
Net financial expenses (112) (94) - -
Income tax expense (614) (514) - -
Effective tax rate -25.0% -25.0% - -
Business net income 1,840 1,537 +19.7% +4.2%
Net margin 19.6% 19.0% - -
Business EPS €1.41 €1.17 +20.5% +5.1%
Average number of shares outstanding (m) 1,305.9 1,314.5 - -
Mid-Single Digit Business EPS Growth at CER in Q2 2015
22
CER: Constant Exchange Rates
(1) Number of shares outstanding on June 30, 2015: 1,306.2m
(1)
Gross Margin Consistent with FY 2015 Expectations
● Cost of Sales (CoS) of €2,938m
in Q2 2015, up +4.8% at CER
● Gross margin of 69.6% in Q2 2015
reflecting 1.0 pt increase over Q2 2014:
● Driven by favorable FX impact
● Positive impact from Genzyme and
Renagel® offsetting negative impact
of Vaccines mix and Lantus® U.S.
23
Q1 Q2 Q3 Q4 Q1 Q2
2014 2015
69.6%
Gross Margin (%)
68.6%
OpEx Grew +14.4% in Reported and +3.7% at CER
in Q2 2015
2424
Q1 Q2 Q3 Q4 Q1 Q2
€3,938m
€3,443m
Operating Expenses (€m)
€1,290m
€1,188m
€2,648m
€2,255m
R&D
SG&A
2014 2015
Targeting mid-single digit OpEx growth at CER in 2015
● Q2 2015 OpEx of €3,938m,
up +3.7% at CER
● R&D expenses of €1,290m
(13.8% of sales), up +8.6%
or stable at CER
● SG&A expenses of €2,648m
(28.2% of sales), up +17.4%
or +5.9% at CER
Regeneron Agreement Terms Provide Critical Investment
Mass for IO Target Discovery and Antibody Development
25
Key Terms for PD-1 inhibitor (REGN2810)Key IO Collaboration Terms
● $265m upfront payment for access to
Regeneron’s research capabilities and
technologies in IO
● Sanofi and Regeneron will invest over
$1bn in R&D (split 75/25)
● Sanofi will re-allocate $75m to IO from
existing collaboration(1)
● Sanofi opt-in rights at Proof of Concept
● After opt-in, partners share R&D costs
and alternate development lead and
U.S. commercialization(2)
● Worldwide profits shared 50/50
● $375m upfront payment
● Sanofi and Regeneron will invest
$650m in R&D (split 50/50)
● Worldwide profits shared 50/50
● Regeneron leads development and
consolidates U.S. sales
● Sanofi consolidates non-U.S. sales
● $375m milestone if sales of a PD-1
and any other collaboration antibody
sold for use in combination with a PD-1
exceed $2bn over 12 months
Exclusive IO antibody collaboration with Regeneron will last up to 8 years(3)
IO: Immuno-Oncology
(1) Sanofi to re-allocate $75m (over 3 years) to IO from its $160m annual contribution to existing collaboration
(2) For antibodies that Regeneron leads development, development costs will be shared equally. For antibodies
that Sanofi leads development, Sanofi will prefund and Regeneron will reimburse 50% of the costs through
the IO collaboration development balance, in an annual amount equal to 10% of the Regeneron share of profits
(3) Five years with an ability to extend the collaboration for selected ongoing programs for an additional three years
Free Cash Flow Increased 29.0% in H1 2015
26
Net Debt (in €m)
€363m
Share
Repurchase
€1,243m€462m
Proceeds
from Issuance
of Shares
CapEx
€667m
Net Cash from
Operating
Activities
Net Debt
Dec 31, 2014
Net Debt
Jun 30, 2015
€801m
Dividend
€3,694m
Acquisitions,
Licensing, Net
of Disposals
Other(1)
(2)
€7,171m
€9,726m€3,751m
(3) (1)
FCF
€3,084m
FCF: Free Cash Flow
(1) Including derivatives related to the financial debt +€302m at December 31st 2014 and +€305m at June 30th 2015
(2) Excluding Restructuring costs
(3) Other including Restructuring costs and Fx impact
Exclusivity Losses and Higher OpEx Expected in H2 2015
● Slower sales growth of Venezuela and Merial
● Expected launch of insulin glargine biosimilar in Europe(1) and Japan
● Generic competition to Plavix® in Japan and Renagel® in Europe
and possibly the U.S.
● Accelerating OpEx growth given:
● New R&D funding of Immuno-Oncology alliance, Toujeo® Phase IV
program, dupilumab Phase III in Asthma
● Investment in Praluent® launch and Toujeo® DTC campaign
2727
H2 2015
(1) Already launched in two Eastern European markets
Business EPS Growth
Approximately +10%(3)
Stable to slightly growing at CER(1,2)
28
(1) Barring major unforeseen adverse events
(2) FY 2014 Business EPS of €5.20
(3) Difference between variation on a reported basis and variation at CER, when applying
June 2015 average exchange rates to the remaining two quarters of the year
Outlook for 2015 - Investing in Future Growth Drivers
FY 2015
FX impact on Business EPS
APPENDICES
R&D Pipeline
29
30
Late Stage Pipeline – Pharma & Vaccines
LixiLan
lixisenatide + insulin glargine
Fixed-Ratio / Type 2 diabetes
patisiran (ALN-TTR02)
siRNA inhibitor targeting TTR
Familial amyloid polyneuropathy
Clostridium difficile
Toxoid vaccine
Praluent® (alirocumab)
Anti-PCSK9 mAb
Hypercholesterolemia, EU
SAR342434
insulin lispro
Type 1+2 diabetes
revusiran (ALN-TTRsc)
siRNA inhibitor targeting TTR
Familial amyloid cardiomyopathy
Rotavirus
Live attenuated tetravalent
Rotavirus oral vaccine
lixisenatide
GLP-1 agonist
Type 2 diabetes, U.S.
sarilumab
Anti-IL6R mAb
Rheumatoid arthritis
Kynamro® (mipomersen)
Apolipoprotein B-100 antisense
Severe HeFH, U.S.
VaxiGrip® QIV IM
Quadrivalent inactivated
influenza vaccine
Dengue
Mild-to-severe
dengue fever vaccine
dupilumab
Anti-IL4Rα mAb
Atopic dermatitis, Asthma
Jevtana® (cabazitaxel)
Metastatic prostate cancer (1L)
PR5i
DTP-HepB-Polio-Hib
Pediatric hexavalent vaccine, U.S., EU
SYNVISC-ONE®
Medical device
Pain in hip OA
30
N
N
N
N New Molecular Entity Immune Mediated Diseases
Rare Diseases
Oncology
Diabetes Solutions
Vaccines
Infectious Diseases
Cardiovascular / Renal
Diseases
Age Related Degenerative
Diseases
Ophthalmology
Biosurgery
Phase III Registration
N
N
NN
Early Stage Pipeline – Pharma & Vaccines
dupilumab
Anti-IL4Rα mAb
Nasal polyposis;
Eosinophilic oesophagitis
isatuximab
Anti-CD38 naked mAb
Multiple myeloma
Rabies VRVg
Purified vero rabies vaccine
vatelizumab
Anti-VLA 2 mAb
Multiple sclerosis
SAR125844
C-MET kinase inhibitor
NSCLC
Meningitis ACYW conj.
2nd generation meningococcal
conjugate infant vaccine
SAR156597
IL4/IL13 Bi-specific mAb
Idiopathic pulmonary fibrosis
GZ402671
Oral GCS Inhibitor
Fabry Disease
Tuberculosis
Recombinant subunit vaccine
sarilumab
Anti-IL6R mAb
Uveitis
olipudase alfa
rhASM
Niemann-Pick type B
Combination
ferroquine / OZ439
Antimalarial
Phase II
N
N
31
N
31
N New Molecular Entity Immune Mediated Diseases
Rare Diseases
Oncology
Diabetes Solutions
Vaccines
Infectious Diseases
Cardiovascular / Renal
Diseases
Age Related Degenerative
Diseases
Ophthalmology
Biosurgery
N
N N
N
Early Stage Pipeline – Pharma & Vaccines
GZ402668
GLD52 (anti-CD52 mAb)
Relapsing multiple sclerosis
SAR566658
Maytansin-loaded anti-CA6 mAb
Solid tumors
GZ402666
neo GAA
Pompe Disease
Streptococcus pneumonia
Meningitis & pneumonia vaccine
SAR113244
Anti-CXCR5 mAb
Systemic lupus erythematosus
SAR408701
Anti-CEACAM5 ADC
Solid tumors
GZ389988
TRKA antagonist
Osteoarthritis
Herpes Simplex Virus Type 2
HSV-2 vaccine
SAR228810
Anti-protofibrillar AB mAb
Alzheimer’s disease
REGN2810
PD-1 inhibitor
Cancer
StarGen®
Gene therapy
Stargardt disease
SAR425899
GLP-1 / GCGR agonist
Diabetes
SAR125844
C-MET kinase inhibitor
Solid tumors
UshStat®
Gene therapy
Usher syndrome 1B
SAR439152
Myosin inhibitor
Hypertrophic cardiomyopathy
Phase I
N
N
N
NN
NN
N
32
N New Molecular Entity Immune Mediated Diseases
Rare Diseases
Oncology
Diabetes Solutions
Vaccines
Infectious Diseases
Cardiovascular / Renal
Diseases
Age Related Degenerative
Diseases
Ophthalmology
Biosurgery
N
N
N
N
33
Phase I Phase II Phase III Registration TOTAL
Oncology 3 2 0 0 5
Diabetes Solutions 1 0 1 1 3
Cardiovascular / Renal
Diseases
1 0 0 1 2
Immune Mediated
Diseases
2 2 2 0 6
Infectious Diseases 0 1 0 0 1
Ophthalmology 2 0 0 0 2
Rare Diseases 2 2 2 0 6
Age Related
Degenerative Diseases
1 0 0 0 1
Vaccines 2 3 3 2 10
TOTAL 14 10 8 4
R&D Pipeline Summary Table(1)
24 12 NMEs & Vaccines
36
33
26
(1) Excluding life cycle management programs
34
Expected R&D Milestones
34
Product Event Timing
Praluent® (alirocumab) Expected EC regulatory decision in Hypercholesterolemia Q3 2015
LixiLan Expected Phase III top line results in Diabetes Q3 2015
Vaxigrip® QIV IM (3+ years) Expected EU regulatory submission Q4 2015
Dengue vaccine Expected regulatory decision in endemic countries Q4 2015
LixiLan Expected U.S. regulatory submission in Diabetes Q4 2015
sarilumab Expected U.S. regulatory submission in Rheumatoid Arthritis Q4 2015
PR5i vaccine (DTP-HepB-Polio-Hib) Expected U.S. regulatory decision Q4 2015
LixiLan Expected EU regulatory submission in Diabetes Q1 2016
PR5i vaccine (DTP-HepB-Polio-Hib) Expected EU regulatory decision Q1 2016
Meningitis ACYW conj. vaccine Expected start of Phase III trial Q1 2016
dupilumab Expected Phase III top line results in Atopic Dermatitis Q1 2016
Rotavirus vaccine Expected regulatory submission in India Q2 2016
insulin lispro Expected Phase III top line results in Diabetes Q2 2016
APPENDICES
FINANCE
35
Business EPS Currency Sensitivity
Currency Exposure on Q2 2015 Sales Currency Average Rates
2015 Currency Sensitivity
36
Q2 2014 Q2 2015 % change
EUR/USD 1.37 1.10 -19.7%
EUR/JPY 140.03 134.14 -4.2%
EUR/CNY 8.54 6.85 -19.8%
EUR/RUB 47,96 58,12 +21.2%
Currency Variation Business EPS Sensitivity
U.S. Dollar -0.05 USD/EUR +EUR 0.10
Japanese Yen +5 JPY/EUR -EUR 0.03
Russian Ruble +10 RUB/EUR -EUR 0.06
€
23.0%
US $
35.6%
Japanese Yen
5.5%
Bristish £
2.0%
Australian $
1.5%
Canadian $
1.5%
Brazilian
Real
3.2%
Chinese Yuan
5.4%
Russian
Ruble
1.6%
Others
19.3 %
Mexican Peso
1.4%
37
Business Net Income Statement
(1) Net of tax
(2) Determined on the basis of Business income before tax, associates and non-controlling interests
(3) Based on an average number of shares outstanding of 1,305.9 million in the second quarter of 2015 and 1,314.5 million in the second quarter of 2014
Second quarter 2015
Net sales 9,378 8,075 16.1% 7,800 6,820 14.4% 887 718 23.5% 691 537 28.7% - -
Other revenues 83 71 16.9% 67 58 15.5% 8 7 14.3% 8 6 33.3% - -
Cost of sales (2,938) (2,608) 12.7% (2,252) (2,058) 9.4% (450) (350) 28.6% (236) (200) 18.0% - -
As % of net sales (31.3%) (32.3%) (28.9%) (30.2%) (50.7%) (48.8%) (34.2%) (37.2%)
Gross profit 6,523 5,538 17.8% 5,615 4,820 16.5% 445 375 18.7% 463 343 35.0% - -
As % of net sales 69.6% 68.6% 72.0% 70.7% 50.2% 52.2% 67.0% 63.9%
Research & development
expenses
(1,290) (1,188) 8.6% (1,104) (1,030) 7.2% (142) (123) 15.4% (44) (35) 25.7% - -
As % of net sales (13.8%) (14.7%) (14.2%) (15.1%) (16.0%) (17.1%) (6.4%) (6.5%)
Selling and general
expenses
(2,648) (2,255) 17.4% (2,216) (1,930) 14.8% (188) (142) 32.4% (244) (183) 33.3% - -
As % of net sales (28.2%) (27.9%) (28.4%) (28.3%) (21.2%) (19.8%) (35.3%) (34.1%)
Other current operating
income/expenses
(20) 54 (11) 42 1 3 5 11 (15) (2)
Share of profit/loss of
associates(1) 30 26 29 25 1 1 - - - -
Net income attributable to
non-controlling interests
(29) (30) (29) (30) - - - - - -
Business operating income 2,566 2,145 19.6% 2,284 1,897 20.4% 117 114 2.6% 180 136 32.4% (15) (2)
As % of net sales 27.4% 26.6% 29.3% 27.8% 13.2% 15.9% 26.0% 25.3%
Financial income and
expenses
(112) (94)
Income tax expense (614) (514)
Tax rate (2) 25.0% 25.0%
Business net income 1,840 1,537 19.7%
As % of net sales 19.6% 19.0%
Business earnings per
share(3)
(in euros)
1.41 1.17 20.5%
OtherGroup Total Pharmaceuticals Vaccines Animal health
change Q2 2015 Q2 2014change Q2 2015 Q2 2014 change Q2 2015 Q2 2014Q2 2014€ million Q2 2015 Q2 2014 change Q2 2015
38
Business Net Income Statement
(1) Net of tax
(2) Determined on the basis of Business income before tax, associates and non-controlling interests
(3) Based on an average number of shares outstanding of 1,307.2 million in the first semester of 2015 and 1,317.2 million in the first semester of 2014
First Half 2015
Net sales 18,188 15,917 14.3% 15,255 13,517 12.9% 1,584 1,346 17.7% 1,349 1,054 28.0%
Other revenues 163 154 5.8% 129 126 2.4% 14 14 - 20 14 42.9% - -
Cost of sales (5,724) (5,124) 11.7% (4,442) (4,046) 9.8% (826) (700) 18.0% (456) (378) 20.6% - -
As % of net sales (31.5%) (32.2%) (29.1%) (29.9%) (52.1%) (52.0%) (33.8%) (35.8%)
Gross profit 12,627 10,947 15.3% 10,942 9,597 14.0% 772 660 17.0% 913 690 32.3% - -
As % of net sales 69.4% 68.8% 71.7% 71.0% 48.7% 49.0% 67.7% 65.5%
Research and development
expenses
(2,489) (2,327) 7.0% (2,143) (2,025) 5.8% (262) (230) 13.9% (84) (72) 16.7% - -
As % of net sales (13.7%) (14.6%) (14.0%) (15.0%) (16.5%) (17.1%) (6.2%) (6.8%)
Selling and general
expenses
(5,086) (4,333) 17.4% (4,310) (3,721) 15.8% (344) (271) 26.9% (432) (341) 26.7% - -
As % of net sales (28.0%) (27.2%) (28.3%) (27.5%) (21.7%) (20.1%) (32.0%) (32.4%)
Other current operating
income/expenses
(87) 29 (39) 19 2 1 5 17 (55) (8)
Share of profit/loss of
associates(1) 61 39 61 33 - 6 - - - -
Net income attributable to
non-controlling interests
(62) (65) (62) (65) - - - - - -
Business operating income 4,964 4,290 15.7% 4,449 3,838 15.9% 168 166 1.2% 402 294 36.7% (55) (8)
As % of net sales 27.3% 27.0% 29.2% 28.4% 10.6% 12.3% 29.8% 27.9%
Financial income and
expenses
(209) (170)
Income tax expense (1,189) (1,036)
Tax rate (2)
25.0% 25.0%
Business net income 3,566 3,084 15.6%
As % of net sales 19.6% 19.4%
Business earnings per
share(3)
(in euros)
2.73 2.34 16.7%
€ million H1 2015 H1 2014 change H1 2015
Group Total Pharmaceuticals Vaccines Animal health
H1 2014 H1 2015 H1 2014
Other
H1 2014 change H1 2015 H1 2014H1 2015change change
Reconciliation of Business Net Income to Consolidated
Net Income Attributable to Equity Holders of Sanofi
39
(1) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations:
€582 million in the second quarter of 2015 and €601 million in the second quarter of 2014
(2) Based on an average number of shares outstanding of 1,305.9 million in the second quarter of 2015 and 1,314.5 million in the second quarter of 2014
€ million Q2 2015 Q2 2014 Change
Business net income 1,840 1,537 19.7%
Amortization of intangible assets(1)
(611) (624)
Impairment of intangible assets (1) (71)
Fair value remeasurement of contingent consideration liabilities 70 (124)
Restructuring costs (28) (84)
Other gains and losses, and litigation - -
Tax effect of: 206 274
amortization of intangible assets 214 207
impairment of intangible assets - 25
fair value remeasurement of contingent consideration liabilities (22) 13
other gains and losses, and litigation - -
restructuring costs 14 29
Other tax items (111) (110)
Share of items listed above attributable to non-controlling interests 2 3
Restructuring costs of associates and joint ventures, and expenses arising from the impact
of acquisitions on associates and joint ventures
(65) (24)
Net income attributable to equity holders of Sanofi 1,302 777 67.6%
Consolidated earnings per share(2)
(in euros) 1.00 0.59
Reconciliation of Business Net Income to Consolidated
Net Income Attributable to Equity Holders of Sanofi
40
(1) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations:
€1,172 million in the first semester of 2015 and €1,258 million in the first semester of 2014
(2) Day one profit on Alnylam shares presented in financial result
(3) Tax on dividends paid to shareholders of Sanofi
(4) Based on an average number of shares outstanding of 1,307.2 million in the first semester of 2015 and 1,317.2 million in the first semester of 2014
€ million H1 2015 H1 2014 Change
Business net income 3,566 3,084 15.6%
Amortization of intangible assets(1)
(1,229) (1,301)
Impairment of intangible assets (28) (74)
Fair value remeasurement of contingent consideration liabilities 71 (132)
Restructuring costs (381) (135)
Other gains and losses, and litigation(2) - 35
Tax effect of: 561 522
amortization of intangible assets 431 451
impairment of intangible assets 10 26
fair value remeasurement of contingent consideration liabilities (15) 14
other gains and losses, and litigation - (13)
restructuring costs 135 44
Other tax items(3)
(111) (110)
Share of items listed above attributable to non-controlling interests 3 4
Restructuring costs of associates and joint ventures, and expenses arising from the impact
of acquisitions on associates and joint ventures
(127) (32)
Net income attributable to equity holders of Sanofi 2,325 1,861 24.9%
Consolidated earnings per share(4)
(in euros) 1.78 1.41
41
Consolidated Income Statements
(1) In 2015, including a tax on dividends paid to shareholders of Sanofi: (111)M€ compared to (110)M€ in 2014
€ million
Net sales 9,378 8,075 18,188 15,917
Other revenues 83 71 163 154
Cost of sales (2,938) (2,608) (5,724) (5,124)
Gross profit 6,523 5,538 12,627 10,947
Research and development expenses (1,290) (1,188) (2,489) (2,327)
Selling and general expenses (2,648) (2,255) (5,086) (4,333)
Other operating income 47 106 83 116
Other operating expenses (67) (52) (170) (87)
Amortization of intangible assets (611) (624) (1,229) (1,301)
Impairment of intangible assets (1) (71) (28) (74)
Fair value remeasurement of contingent consideration liabilities 70 (124) 71 (132)
Restructuring costs (28) (84) (381) (135)
Operating income 1,995 1,246 3,398 2,674
Financial expenses (134) (145) (267) (292)
Financial income 22 51 58 157
Income before tax and associates and joint ventures 1,883 1,152 3,189 2,539
Income tax expense(1)
(519) (350) (739) (624)
Share of profit / loss of associates and joint ventures (35) 2 (66) 7
Net income 1,329 804 2,384 1,922
Net income attributable to non-controlling interests 27 27 59 61
Net income attributable to equity holders of Sanofi 1,302 777 2,325 1,861
Average number of shares outstanding (million) 1,305.9 1,314.5 1,307.2 1,317.2
Consolidated earnings per share (in euros) 1.00 0.59 1.78 1.41
Q2 2014Q2 2015 H1 2015 H1 2014
42
Cash Flow Statements
(1) Excluding restructuring costs
€ million H1 2015 H1 2014
Business net income 3,566 3,084
Depreciation, amortization and impairment of property, plant and equipment and software 628 582
Gains and losses on disposals of non-current assets, net of tax (44) (97)
Other non cash items (218) (98)
Operating cash flow before changes in working capital(1)
3,932 3,471
Changes in working capital(1)
(181) (552)
Acquisitions of property, plant and equipment and software (667) (529)
Free cash flow
(1)
3,084 2,390
Acquisitions of intangible assets excluding software (280) (108)
Acquisitions of investments in consolidated undertakings including assumed debt (169) (1,679)
Restructuring costs (345) (382)
Proceeds from disposals of property, plant and equipment, intangible assets and other
non-current assets net of tax 86 179
Issuance of Sanofi shares 462 240
Dividends paid to shareholders of Sanofi (3,694) (3,676)
Acquisition of treasury shares (1,243) (1,010)
Disposals of treasury shares 1 -
Transactions with non-controlling interests including dividends (16) (6)
Foreign exchange impact (391) (37)
Other items (50) (62)
Change in net debt (2,555) (4,151)
43
Balance Sheets
ASSETS
€ million
June 30, 2015 Dec 31, 2014
LIABILITIES & EQUITY
€ million
June 30, 2015 Dec 31, 2014
Property, plant and equipment 10,540 10,396 Equity attributable to equity holders of Sanofi 56,618 56,120
Intangible assets (including goodwill) 55,062 53,740 Equity attributable to non-controlling interests 156 148
Non-current financial assets & investments in
associates and deferred tax assets
10,296 9,819 Total equity 56,774 56,268
Non-current assets 75,898 73,955 Long-term debt 10,770 13,276
Non-current liabilities related to business
combinations and to non-controlling interests
1,132 1,133
Provisions and other non-current liabilities 9,206 9,578
Deferred tax liabilities 3,742 4,105
Non-current liabilities 24,850 28,092
Inventories, accounts receivable and other current
assets
17,308 16,086 Accounts payable & Other current liabilities 12,192 11,363
Cash and cash equivalents 4,701 7,341
Current liabilities related to business combinations
and to non-controlling interests
141 131
Current assets 22,009 23,427 Short-term debt and current portion of long-term debt 3,962 1,538
Current liabilities 16,295 13,032
Assets held for sale or exchange 16 10
Liabilities related to assets held for sale or
exchange
4 -
TOTAL ASSETS 97,923 97,392 TOTAL LIABILITIES & EQUITY 97,923 97,392

Weitere ähnliche Inhalte

Was ist angesagt?

2016/09 – BoA-ML Healthcare Conference
2016/09 – BoA-ML Healthcare Conference2016/09 – BoA-ML Healthcare Conference
2016/09 – BoA-ML Healthcare ConferenceSanofi
 
Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi Sanofi
 
General Meeting 2016
General Meeting 2016General Meeting 2016
General Meeting 2016Sanofi
 
2016/03 – Cowen HC Conference
2016/03 – Cowen HC Conference2016/03 – Cowen HC Conference
2016/03 – Cowen HC ConferenceSanofi
 
Q1 2017 Results by Sanofi
Q1 2017 Results by SanofiQ1 2017 Results by Sanofi
Q1 2017 Results by SanofiSanofi
 
2015/05 – Deutsche Bank HC Conference
2015/05 – Deutsche Bank HC Conference2015/05 – Deutsche Bank HC Conference
2015/05 – Deutsche Bank HC ConferenceSanofi
 
General Meeting 2015
General Meeting 2015General Meeting 2015
General Meeting 2015Sanofi
 
2015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 190520152015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 19052015Sanofi
 
2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HCSanofi
 
2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC ConferenceSanofi
 
Sanofi - Corporate Presentation
Sanofi - Corporate PresentationSanofi - Corporate Presentation
Sanofi - Corporate PresentationSanofi
 
2016/06 – IR – Business swap with Boehringer Ingelheim
2016/06 – IR – Business swap with Boehringer Ingelheim2016/06 – IR – Business swap with Boehringer Ingelheim
2016/06 – IR – Business swap with Boehringer IngelheimSanofi
 
Q2 2017 Results by Sanofi
Q2 2017 Results by SanofiQ2 2017 Results by Sanofi
Q2 2017 Results by SanofiSanofi
 
2015/07 – IR – Praluent
2015/07 – IR – Praluent2015/07 – IR – Praluent
2015/07 – IR – PraluentSanofi
 
Q3 2017 Results
Q3 2017 Results Q3 2017 Results
Q3 2017 Results Sanofi
 
Annual Results 2016
Annual Results 2016Annual Results 2016
Annual Results 2016Sanofi
 
2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi ManagementSanofi
 
2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC ConferenceSanofi
 
General Meeting 2017
General Meeting 2017General Meeting 2017
General Meeting 2017Sanofi
 
2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab2016/10 – IR call – Dupilumab
2016/10 – IR call – DupilumabSanofi
 

Was ist angesagt? (20)

2016/09 – BoA-ML Healthcare Conference
2016/09 – BoA-ML Healthcare Conference2016/09 – BoA-ML Healthcare Conference
2016/09 – BoA-ML Healthcare Conference
 
Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi Q3 2016 Results by Sanofi
Q3 2016 Results by Sanofi
 
General Meeting 2016
General Meeting 2016General Meeting 2016
General Meeting 2016
 
2016/03 – Cowen HC Conference
2016/03 – Cowen HC Conference2016/03 – Cowen HC Conference
2016/03 – Cowen HC Conference
 
Q1 2017 Results by Sanofi
Q1 2017 Results by SanofiQ1 2017 Results by Sanofi
Q1 2017 Results by Sanofi
 
2015/05 – Deutsche Bank HC Conference
2015/05 – Deutsche Bank HC Conference2015/05 – Deutsche Bank HC Conference
2015/05 – Deutsche Bank HC Conference
 
General Meeting 2015
General Meeting 2015General Meeting 2015
General Meeting 2015
 
2015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 190520152015/05 - Berenberg presentation 19052015
2015/05 - Berenberg presentation 19052015
 
2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC
 
2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference2017/01 - JP Morgan HC Conference
2017/01 - JP Morgan HC Conference
 
Sanofi - Corporate Presentation
Sanofi - Corporate PresentationSanofi - Corporate Presentation
Sanofi - Corporate Presentation
 
2016/06 – IR – Business swap with Boehringer Ingelheim
2016/06 – IR – Business swap with Boehringer Ingelheim2016/06 – IR – Business swap with Boehringer Ingelheim
2016/06 – IR – Business swap with Boehringer Ingelheim
 
Q2 2017 Results by Sanofi
Q2 2017 Results by SanofiQ2 2017 Results by Sanofi
Q2 2017 Results by Sanofi
 
2015/07 – IR – Praluent
2015/07 – IR – Praluent2015/07 – IR – Praluent
2015/07 – IR – Praluent
 
Q3 2017 Results
Q3 2017 Results Q3 2017 Results
Q3 2017 Results
 
Annual Results 2016
Annual Results 2016Annual Results 2016
Annual Results 2016
 
2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management2015/11 - Meet Sanofi Management
2015/11 - Meet Sanofi Management
 
2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference2016/01 - JP Morgan HC Conference
2016/01 - JP Morgan HC Conference
 
General Meeting 2017
General Meeting 2017General Meeting 2017
General Meeting 2017
 
2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab2016/10 – IR call – Dupilumab
2016/10 – IR call – Dupilumab
 

Andere mochten auch

Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi Sanofi
 
Assemblée Générale 2016
Assemblée Générale 2016Assemblée Générale 2016
Assemblée Générale 2016Sanofi
 
Learning Technologies Presentation - Transforming Formal Learning
Learning Technologies Presentation - Transforming Formal Learning Learning Technologies Presentation - Transforming Formal Learning
Learning Technologies Presentation - Transforming Formal Learning DPG plc
 
25+ iPad Apps for Integrating Technology into the Writing Process
25+ iPad Apps for Integrating Technology into the Writing Process 25+ iPad Apps for Integrating Technology into the Writing Process
25+ iPad Apps for Integrating Technology into the Writing Process Monica Burns
 
How to Increase Your Traffic by Deleting Your Content - Todd Tresidder
How to Increase Your Traffic by Deleting Your Content - Todd TresidderHow to Increase Your Traffic by Deleting Your Content - Todd Tresidder
How to Increase Your Traffic by Deleting Your Content - Todd TresidderLeslie Samuel
 
Strategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisStrategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisBruno Rakotozafy
 
Herramientas digitales que todo emprendedor debe tener
Herramientas digitales que todo emprendedor debe tenerHerramientas digitales que todo emprendedor debe tener
Herramientas digitales que todo emprendedor debe tenerWe Enjoy Social Media
 
SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO
SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO
SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO eugeniadelafuente
 
Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...
Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...
Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...Ctvrtkoncz
 

Andere mochten auch (12)

Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi Q3 2015 RESULTS by Sanofi
Q3 2015 RESULTS by Sanofi
 
Assemblée Générale 2016
Assemblée Générale 2016Assemblée Générale 2016
Assemblée Générale 2016
 
Cipla roche
Cipla rocheCipla roche
Cipla roche
 
Learning Technologies Presentation - Transforming Formal Learning
Learning Technologies Presentation - Transforming Formal Learning Learning Technologies Presentation - Transforming Formal Learning
Learning Technologies Presentation - Transforming Formal Learning
 
25+ iPad Apps for Integrating Technology into the Writing Process
25+ iPad Apps for Integrating Technology into the Writing Process 25+ iPad Apps for Integrating Technology into the Writing Process
25+ iPad Apps for Integrating Technology into the Writing Process
 
How to Increase Your Traffic by Deleting Your Content - Todd Tresidder
How to Increase Your Traffic by Deleting Your Content - Todd TresidderHow to Increase Your Traffic by Deleting Your Content - Todd Tresidder
How to Increase Your Traffic by Deleting Your Content - Todd Tresidder
 
Strategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisStrategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi Aventis
 
Herramientas digitales que todo emprendedor debe tener
Herramientas digitales que todo emprendedor debe tenerHerramientas digitales que todo emprendedor debe tener
Herramientas digitales que todo emprendedor debe tener
 
SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO
SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO
SLIDESHARE, UNA OPORTUNIDAD PARA TU NEGOCIO
 
Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...
Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...
Jak nakrmit Facebook firemní stránku a Instagram obsahem, co její fanoušci do...
 
cholera
choleracholera
cholera
 
Ucom Agência Jr de Comunicação Uniron
Ucom Agência Jr de Comunicação UnironUcom Agência Jr de Comunicação Uniron
Ucom Agência Jr de Comunicação Uniron
 

Ähnlich wie Q2 2015 RESULTS by Sanofi

Q2 2019 Results
Q2 2019 ResultsQ2 2019 Results
Q2 2019 ResultsSanofi
 
Q2 2018 Results
Q2 2018 ResultsQ2 2018 Results
Q2 2018 ResultsSanofi
 
Q4 and Full Year 2018 Results
Q4 and Full Year 2018 ResultsQ4 and Full Year 2018 Results
Q4 and Full Year 2018 ResultsSanofi
 
Q3 2019 Results
Q3 2019 ResultsQ3 2019 Results
Q3 2019 ResultsSanofi
 
Merck: Q2 2014 Results Conference Call
Merck: Q2 2014 Results Conference CallMerck: Q2 2014 Results Conference Call
Merck: Q2 2014 Results Conference CallMerck
 
Q1 2019 Results
Q1 2019 ResultsQ1 2019 Results
Q1 2019 ResultsSanofi
 
Q1 2018 Results
Q1 2018 ResultsQ1 2018 Results
Q1 2018 ResultsSanofi
 
Q4 and FY 2020 results
Q4 and FY 2020 resultsQ4 and FY 2020 results
Q4 and FY 2020 resultsSanofi
 
Merck: Q1 2014 Results Conference Call
Merck: Q1 2014 Results Conference Call Merck: Q1 2014 Results Conference Call
Merck: Q1 2014 Results Conference Call Merck
 
Vivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 PresentationVivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 PresentationJigar Savla
 
Q3 2015 Financial Results October 19, 2015
Q3 2015 Financial Results October 19, 2015Q3 2015 Financial Results October 19, 2015
Q3 2015 Financial Results October 19, 2015Valeant_Pharmaceuticals
 
Luxottica Group 1Q 2014 Results Presentation
Luxottica Group 1Q 2014 Results PresentationLuxottica Group 1Q 2014 Results Presentation
Luxottica Group 1Q 2014 Results PresentationLuxottica Group
 
Q22015 earnings deck final august 11 revised
Q22015 earnings deck final august 11 revisedQ22015 earnings deck final august 11 revised
Q22015 earnings deck final august 11 revisedValeant_Pharmaceuticals
 
FY/Q4 2013 Investor Conference Call Presentation Charts
FY/Q4 2013 Investor Conference Call Presentation ChartsFY/Q4 2013 Investor Conference Call Presentation Charts
FY/Q4 2013 Investor Conference Call Presentation ChartsBayer
 
Investors Presentation 9M|2020 Results
Investors Presentation 9M|2020 ResultsInvestors Presentation 9M|2020 Results
Investors Presentation 9M|2020 ResultsAndreGro
 
Q4 2015 3 m earnings presentation
Q4 2015 3 m earnings presentationQ4 2015 3 m earnings presentation
Q4 2015 3 m earnings presentationInvestors_3M
 

Ähnlich wie Q2 2015 RESULTS by Sanofi (20)

Q2 2019 Results
Q2 2019 ResultsQ2 2019 Results
Q2 2019 Results
 
Q2 2018 Results
Q2 2018 ResultsQ2 2018 Results
Q2 2018 Results
 
Q4 and Full Year 2018 Results
Q4 and Full Year 2018 ResultsQ4 and Full Year 2018 Results
Q4 and Full Year 2018 Results
 
Q3 2019 Results
Q3 2019 ResultsQ3 2019 Results
Q3 2019 Results
 
Merck: Q2 2014 Results Conference Call
Merck: Q2 2014 Results Conference CallMerck: Q2 2014 Results Conference Call
Merck: Q2 2014 Results Conference Call
 
Q1 2019 Results
Q1 2019 ResultsQ1 2019 Results
Q1 2019 Results
 
Q1 2018 Results
Q1 2018 ResultsQ1 2018 Results
Q1 2018 Results
 
Q4 and FY 2020 results
Q4 and FY 2020 resultsQ4 and FY 2020 results
Q4 and FY 2020 results
 
Merck: Q1 2014 Results Conference Call
Merck: Q1 2014 Results Conference Call Merck: Q1 2014 Results Conference Call
Merck: Q1 2014 Results Conference Call
 
Vivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 PresentationVivimed labs ltd_3QFY15 Presentation
Vivimed labs ltd_3QFY15 Presentation
 
Q3 2015 Financial Results October 19, 2015
Q3 2015 Financial Results October 19, 2015Q3 2015 Financial Results October 19, 2015
Q3 2015 Financial Results October 19, 2015
 
Luxottica Group 1Q 2014 Results Presentation
Luxottica Group 1Q 2014 Results PresentationLuxottica Group 1Q 2014 Results Presentation
Luxottica Group 1Q 2014 Results Presentation
 
4 q15
4 q154 q15
4 q15
 
Q22015 earnings deck final august 11 revised
Q22015 earnings deck final august 11 revisedQ22015 earnings deck final august 11 revised
Q22015 earnings deck final august 11 revised
 
Q22015 earnings deck final
Q22015 earnings deck finalQ22015 earnings deck final
Q22015 earnings deck final
 
FY/Q4 2013 Investor Conference Call Presentation Charts
FY/Q4 2013 Investor Conference Call Presentation ChartsFY/Q4 2013 Investor Conference Call Presentation Charts
FY/Q4 2013 Investor Conference Call Presentation Charts
 
Investors Presentation 9M|2020 Results
Investors Presentation 9M|2020 ResultsInvestors Presentation 9M|2020 Results
Investors Presentation 9M|2020 Results
 
Q4 2015 3 m earnings presentation
Q4 2015 3 m earnings presentationQ4 2015 3 m earnings presentation
Q4 2015 3 m earnings presentation
 
1 q15
1 q151 q15
1 q15
 
Results Q2 2015
Results Q2 2015Results Q2 2015
Results Q2 2015
 

Mehr von Sanofi

Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsFourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsSanofi
 
Third quarter 2023 Results
Third quarter 2023 ResultsThird quarter 2023 Results
Third quarter 2023 ResultsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023Sanofi
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlightsSanofi
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlightsSanofi
 
First quarter 2023 results
First quarter 2023 resultsFirst quarter 2023 results
First quarter 2023 resultsSanofi
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlightsSanofi
 
Sanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi
 
2022 full-year results highlights
2022 full-year results highlights2022 full-year results highlights
2022 full-year results highlightsSanofi
 
L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 Sanofi
 
Presentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsPresentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsSanofi
 
Q3 2022 Results
Q3 2022 ResultsQ3 2022 Results
Q3 2022 ResultsSanofi
 
Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Sanofi
 
Second quarter 2022 results
Second quarter 2022 results Second quarter 2022 results
Second quarter 2022 results Sanofi
 
Q1 First quarter results
Q1 First quarter resultsQ1 First quarter results
Q1 First quarter resultsSanofi
 
Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Sanofi
 
First quarter 2022 results
First quarter 2022 resultsFirst quarter 2022 results
First quarter 2022 resultsSanofi
 
Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Sanofi
 

Mehr von Sanofi (20)

Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 resultsFourth quarter and full year 2023 results
Fourth quarter and full year 2023 results
 
Third quarter 2023 Results
Third quarter 2023 ResultsThird quarter 2023 Results
Third quarter 2023 Results
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023L’essentiel des résultats du T2 2023
L’essentiel des résultats du T2 2023
 
Q2 2023 results highlights
Q2 2023 results highlightsQ2 2023 results highlights
Q2 2023 results highlights
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlights
 
First quarter 2023 results
First quarter 2023 resultsFirst quarter 2023 results
First quarter 2023 results
 
Q1 2023 results highlights
Q1 2023 results highlightsQ1 2023 results highlights
Q1 2023 results highlights
 
Sanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 resultsSanofi Q4 and full year 2022 results
Sanofi Q4 and full year 2022 results
 
2022 full-year results highlights
2022 full-year results highlights2022 full-year results highlights
2022 full-year results highlights
 
L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022 L’essentiel des résultats annuels 2022
L’essentiel des résultats annuels 2022
 
Presentation of the Q3 2022 Results
Presentation of the Q3 2022 ResultsPresentation of the Q3 2022 Results
Presentation of the Q3 2022 Results
 
Q3 2022 Results
Q3 2022 ResultsQ3 2022 Results
Q3 2022 Results
 
Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022Résultats financiers du 3e trimestre 2022
Résultats financiers du 3e trimestre 2022
 
Second quarter 2022 results
Second quarter 2022 results Second quarter 2022 results
Second quarter 2022 results
 
Q1 First quarter results
Q1 First quarter resultsQ1 First quarter results
Q1 First quarter results
 
Résultats du premier trimestre 2022
Résultats du premier trimestre 2022Résultats du premier trimestre 2022
Résultats du premier trimestre 2022
 
First quarter 2022 results
First quarter 2022 resultsFirst quarter 2022 results
First quarter 2022 results
 
Q4 and Full Year Results 2021
Q4 and Full Year Results 2021Q4 and Full Year Results 2021
Q4 and Full Year Results 2021
 

Kürzlich hochgeladen

Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024Osisko Gold Royalties Ltd
 
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper PotentialAdvancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper Potentialnicola_mining
 
Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024nicola_mining
 
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDFWWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDFMichael Claudio
 
Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023Deutsche EuroShop AG
 
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24Deutsche EuroShop AG
 
Terna Capital Markets Day 2024 Presentation
Terna Capital Markets Day 2024 PresentationTerna Capital Markets Day 2024 Presentation
Terna Capital Markets Day 2024 PresentationTerna SpA
 

Kürzlich hochgeladen (7)

Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
 
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper PotentialAdvancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
 
Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024
 
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDFWWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
 
Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023
 
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24
 
Terna Capital Markets Day 2024 Presentation
Terna Capital Markets Day 2024 PresentationTerna Capital Markets Day 2024 Presentation
Terna Capital Markets Day 2024 Presentation
 

Q2 2015 RESULTS by Sanofi

  • 2. 2 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • 4. Q2 2015 - A Solid Quarterly Performance 4 Delivering mid-single digit sales growth Posting solid financial results Bringing innovative medicines to market GBUs: Global Business Units (1) On a reported basis, Q2 2015 sales were up +16.1% (2) On a reported basis, Q2 2015 Business EPS was up +20.5% (3) FDA submissions of lixisenatide, LixiLan and sarilumab (4) Effective January 1, 2016 Building a sustainable path forward 11 22 33 44 ● Higher OpEx driven by investment in new launches ● Business EPS up +5.1% at CER(2) ● Sales up +4.9% at CER(1) ● Sales growth across all geographies and businesses except Diabetes ● Praluent®: FDA approval and positive CHMP opinion ● Three regulatory filings expected in H2 2015(3) ● New alliance with Regeneron in Immuno-Oncology ● Reorganization around five GBUs recently announced(4)
  • 5. FX Impact +€0.18 Incremental EPS at CER +€0.06 Q2 2014 Q2 2015 Net Sales Business EPS Solid Sales and Business EPS Delivered in Q2 2015 5 (1) On a reported basis, Q2 2015 sales were up +16.1% and Business EPS was up +20.5% +5.1% at CER(1) FX Impact Q2 2015 +€910m Incremental Sales at CER +€393m Q2 2014 +4.9% at CER(1) €8,075m €9,378m €1.17 €1.41
  • 6. Q2 2015 Sales by Business Areas (1) Q2 2015 sales were up +4.9% at CER and +16.1% on a reported basis Growth at CER Genzyme Generics Consumer Healthcare Diabetes Oncology €907m €520m €890m €1,988m €390m +26.6% +9.2% +1.3% -3.8% +3.6% Sales Growth Delivered Across All Businesses in Q2 2015 Except for Diabetes(1) % of Sales 9.7% 9.5% 21.2% 5.5% 4.2% Animal Health Vaccines €691m €887m +14.2% +8.6%9.5% 7.4% Pharmaceuticals €7,800m +3.7%83.1% 6 Established Products €3,105m +3.1%33.0%
  • 7. Sales Growth at CER Q1 2015 Q2 2015 U.S. -12.0% -14.0% Western EU +4.7% +6.5% Emerging Markets +18.5% +17.0% RoW -6.0% +4.8% Worldwide -3.2% -3.8% Q2 2015 Diabetes Sales Consistent with Previous Quarter 21.2%78.8% 57% 43% U.S. ex U.S. Diabetes Sales €1,988m -3.8% at CER Total Group Sales excluding Diabetes €7,390m +7.3% at CER Q2 2015 Diabetes Sales by Geographies (in €m) €854m +11.2% at CER €1,134m -14.0% at CER Expected launch of insulin glargine biosimilar in Europe(1) and Japan in H2 2015 7 (1) Already launched in two Eastern European markets
  • 8. 0 1 000 2 000 3 000 4 000 5 000 6 000 7 000 Week1 Week2 Week3 Week4 Week5 Week6 Week7 Week8 Week9 Week10 Week11 Week12 Week13 Week14 Week15 Week16 0 10 20 30 40 50 60 70 80 Week1 Week2 Week3 Week4 Week5 Week6 Week7 Week8 Week9 Week10 Week11 Week12 Week13 Week14 Week15 Week16 Basal Market NRx Shares week of April 3 - week of July 17, 2015 Total glargine 67.1% Levemir® 25.6% Share (%) (2) (1) Encouraging U.S. Launch Metrics and Global Launch Ongoing (1) Basal market includes Toujeo®, Lantus®, Levemir® (a Novo Nordisk brand) and NPH - Source: IMS Weekly Data (2) Total glargine includes Toujeo® and Lantus® (3) Source: IMS Weekly Data 8 Toujeo® Market Access as of August 1, 2015 % Lives Covered 28% 45% 0% 20% 40% 60% 80% 100% Commercial Medicare Tier 2 Tier 2 Tier 3 91% 73% Toujeo® TRx & NRx Volume week of April 3 - week of July 17, 2015 NRx 4,507 Cumulative NRx 40,891 Rx (absolute) Cumulative TRx 51,829 TRx 6,539 (3) EU launch ongoing and approval in Japan, Canada, Australia recently granted
  • 9. Rare Disease Franchise Sustained Growth Momentum and Strengthened Leadership(1) in Q2 2015 9 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Others Fabrazyme Myozyme Cerdelga Cerezyme Genzyme Rare Disease Sales (€m) €647m +9.1% at CER €540m €146m €199m €121m €165m (1) Cerezyme® + Cerdelga® value share is 74% and Fabrazyme® value share is 58% based on Q2 2015 reported sales by Sanofi and Shire (2) Cerdelga® sales were €16m in Q2 2015 (2) & Others
  • 10. Multiple Sclerosis Franchise Sales Now Annualizing(1) Over €1bn 10 Genzyme Multiple Sclerosis Sales (€m) Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Lemtrada Aubagio €260m +118.4% at CER €103m €56m €204m ® New Global Campaign (1) Multiplying Q2 2015 sales of €260m by four provides a hypothetical annual run rate of over €1bn sales * AUBAGIO® (teriflunomide) is effective across key measures of disease activity: sustained disability progression (14 mg only), annualized relapse rate, and MRI activity. Common side effects with AUBAGIO led to treatment discontinuation rates ≤3.3% in clinical trials.
  • 11. A Breakthrough Innovation to Help Reduce the Burden of Dengue(2) Vaccines Showed Broad Sales Momentum in Q2 2015 11 Sanofi Pasteur Sales (€m) Q2 2015 €887m Q2 2014 €718m Other Adult Boosters Travel/Endemic Polio/Pertussis/Hib Influenza Vaccines Meningitis/Pneumo (1) +8.6% at CER (1) Includes VaxServe, a U.S. healthcare supplier serving primary care physician offices, community immunization providers, immunizing pharmacies, travel clinics and corporations (2) WHO, 2012, Global Strategy for Dengue Prevention and Control ● Regulatory submissions in key endemic countries in Asia and Latin America completed in June 2015 ● First license anticipated before year-end 2015 Targeting over 65m doses of flu vaccines to be distributed in the U.S. in 2015
  • 12. Merial Sales Growth (at CER) Animal Health Continued its Strong Recovery in Q2 2015 12 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 -5.7% -6.3%-6.4% -1.6% +12.7% +6.2% +11.5% +13.5% +14.2% Five consecutive quarters of strong sales growth NexGard® U.S. Campaign (1) Merial sales growth excluding NexGard® was +7.8% at CER in Q2 2015 (1)
  • 13. (1) World excluding U.S., Canada, Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, the Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, South Korea, Australia, and New Zealand (2) RoW: Japan, South Korea, Canada, Australia, and New Zealand Sales Growth Delivered Across All Geographies in Q2 2015 33.9% 34.7% 21.3% 10.1% 13 (1) €602m €616m €934m €982m Africa & Middle East Eastern Europe, Russia & Turkey Asia Latin America +3.0% +9.3% +7.1%Growth at CER +9.0% Emerging Markets Sales by Region Emerging Markets €3,182m +7.5% at CER U.S. €3,250m +2.1% at CER Western EU €1,998m +3.4% at CER RoW €948m +8.2% at CER (2) Q2 2015 Sales by Geographies (in €m)
  • 14. 14 New Strategic Alliance with Regeneron to Develop Cancer Treatments in Emerging Field of Immuno-Oncology ● Establish Sanofi’s presence in immuno-oncology, a rapidly growing and promising approach to treat cancer  Significant unmet needs remain despite advances shown with checkpoint inhibitors ● Expand our oncology pipeline, developing best-in-class new antibodies and novel combination products(1)  Alliance includes PD-1(2) in Phase I and a portfolio of antibodies, including LAG3, GITR and PD-L1 currently in Preclinical development(3) ● Accelerate development of multiple drug candidates in a fast-evolving IO field with a scale and focus beyond our existing discovery agreement 1 2 Committing to Immuno Oncology 3 PD-1: Programmed death protein 1 LAG-3: Lymphocyte activation gene 3 PD-L1: Programmed death ligand 1 GITR: Glucocorticoid-Induced Tumor-necrosis-factor-Receptor-related protein IO: Immuno-Oncology (1) Including bi-specifics antibodies (2) REGN2810 (3) Subject to opting in
  • 15. 15 Ready to Launch Praluent® (alirocumab) in the U.S. and EU Positive CHMP opinion on July 23, 2015(1)  Indicated in adults with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidaemia, as an adjunct to diet in patients unable to reach their LDL-C goals with a maximally-tolerated statin and patients who are statin intolerant, or for whom a statin is contraindicated FDA approval granted on July 24, 2015  Indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol (LDL-C) (1) EC regulatory decision expected in late September 2015 75 mg dose 150 mg dose
  • 16. (1) ELIXA evaluated CV outcomes in Type 2 Diabetes patients after Acute Coronary Syndrome during treatment with lixisenatide (2) LixiLan is a once-daily fixed-ratio combination of insulin glargine and lixisenatide (3) LixiLan-O evalutates the combination of insulin glargine and lixisenatide in patients insufficiently controlled on OADs. LixiLan-L focuses on patients not at goal on basal insulin. The ongoing LixiLan-L study will be completed in Q3 2015. Following an analysis of results from both Phase III studies, LixiLan-O and LixiLan-L, Sanofi will determine the next steps in the regulatory process. Currently, regulatory submissions are planned for Q4 2015 in the U.S. and Q1 2016 in the EU. (4) SARIL-RA-TARGET, SARIL-RA-EASY and SARIL-RA-ASCERTAIN Additional Clinical Milestones and Regulatory Filings Expected in H2 2015 Key Milestones in H2 2015 16 Type 2 Diabetes Positive ELIXA study results supported U.S. regulatory submission in late July 2015(1) Type 2 Diabetes Positive LixiLan-O top-line results demonstrated superiority over insulin glargine or lixisenatide on HbA1c reduction(3) LixiLan-L results expected in Q3 2015(3) (2) Rheumatoid Arthritis 3 Phase III trials recently met their primary endpoints(4) Regulatory submission expected in late 2015 in the U.S. and Q4 2016 in EU sarilumablixisenatide
  • 17.  Diabetes  Cardiovascular Diabetes & Cardio- vascular P. Witz  Rare diseases  Multiple Sclerosis  Oncology  Immunology Sanofi Genzyme (Specialty Care) D. Meeker  CHC  Established products  Generics General Medicines & Emerging Markets P. Guenter Sanofi Pasteur (Vaccines) O. Charmeil Merial (Animal Health) C. Hellmann  Human vaccines  Animal Health products  Emerging markets(1) & A New Organizational Model with Five Global Business Units Is a Necessary Step to Drive Focus and Simplification 17 (1) All pharmaceutical businesses in Emerging markets to report to General Medicine & Emerging Markets GBU (2) Functions include Research & Development, Industrial Affairs, Finance, Human Resources, Business Development & Strategy, External Affairs, Information Systems, Medical, Legal, Compliance, Procurement (not an exhaustive list of functions) (3) The process of legal and social consultation will be followed as required  Similar to R&D and Industrial Affairs, all functions will be globalized(2) New organization implemented beginning in January 2016(3)
  • 18. Sanofi to Host an IR Seminar in Q4 2015 18 ● Outlining a roadmap towards 2020 ● Sharing the outcome of the ongoing business review ● Presenting further progress of our R&D pipeline ● Offering opportunities to interact with management Friday November 6th, 2015 from 8:30 to 16:00 in Sanofi HQ - Paris 18 Meet Management
  • 19. FINANCIAL RESULTS Jérôme Contamine Executive Vice President, Chief Financial Officer 19
  • 20. Net Sales(1) Business EPS 20 Sustained U.S. Dollar Strength Led to Strong FX Tailwind on Top and Bottom Line Again in Q2 2015 (1) Main currency impact on sales in Q2 2015: U.S. Dollar (+€645m); Chinese Yuan (+€99m); Brazilian Real (-€33m); Russian Ruble (-€31m) Quarterly Currency Impact -6.2% -€497m -5.5% -€443m -1.0% -€81m +9.9% +€782m Q1 2015 Q1 2014 Q2 2014 Q3 2014 Q4 2014 +2.7% +€229m Q1 2015 Q1 2014 Q2 2014 Q3 2014 Q4 2014 -9.1% -€0.11 -8.9% -€0.10 -€0.03 -2.2% +1.5% +€0.02 +10.2% +€0.12 Q2 2015 Q2 2015 +11.2% +€910m +15.4% +€0.18
  • 21. CER: Constant Exchange Rates 21 Business Operating Income Up +4.7% at CER Despite OpEx Increase of +3.7% at CER in Q2 2015 €m Q2 2015 Q2 2014 % Change (reported €) % Change (CER) Net sales 9,378 8,075 +16.1% +4.9% Other revenues 83 71 +16.9% +0.0% Cost of sales (2,938) (2,608) +12.7% +4.8% Gross profit 6,523 5,538 +17.8% +4.8% R&D (1,290) (1,188) +8.6% -0.3% SG&A (2,648) (2,255) +17.4% +5.9% Other current operating income & expenses (20) 54 - - Share of Profit/Loss of associates 30 26 - - Minority interests (29) (30) - - Business operating income 2,566 2,145 +19.6% +4.7% Business operating margin 27.4% 26.6% - -
  • 22. 22 €m Q2 2015 Q2 2014 % Change (reported €) % Change (CER) Business operating income 2,566 2,145 +19.6% +4.7% Net financial expenses (112) (94) - - Income tax expense (614) (514) - - Effective tax rate -25.0% -25.0% - - Business net income 1,840 1,537 +19.7% +4.2% Net margin 19.6% 19.0% - - Business EPS €1.41 €1.17 +20.5% +5.1% Average number of shares outstanding (m) 1,305.9 1,314.5 - - Mid-Single Digit Business EPS Growth at CER in Q2 2015 22 CER: Constant Exchange Rates (1) Number of shares outstanding on June 30, 2015: 1,306.2m (1)
  • 23. Gross Margin Consistent with FY 2015 Expectations ● Cost of Sales (CoS) of €2,938m in Q2 2015, up +4.8% at CER ● Gross margin of 69.6% in Q2 2015 reflecting 1.0 pt increase over Q2 2014: ● Driven by favorable FX impact ● Positive impact from Genzyme and Renagel® offsetting negative impact of Vaccines mix and Lantus® U.S. 23 Q1 Q2 Q3 Q4 Q1 Q2 2014 2015 69.6% Gross Margin (%) 68.6%
  • 24. OpEx Grew +14.4% in Reported and +3.7% at CER in Q2 2015 2424 Q1 Q2 Q3 Q4 Q1 Q2 €3,938m €3,443m Operating Expenses (€m) €1,290m €1,188m €2,648m €2,255m R&D SG&A 2014 2015 Targeting mid-single digit OpEx growth at CER in 2015 ● Q2 2015 OpEx of €3,938m, up +3.7% at CER ● R&D expenses of €1,290m (13.8% of sales), up +8.6% or stable at CER ● SG&A expenses of €2,648m (28.2% of sales), up +17.4% or +5.9% at CER
  • 25. Regeneron Agreement Terms Provide Critical Investment Mass for IO Target Discovery and Antibody Development 25 Key Terms for PD-1 inhibitor (REGN2810)Key IO Collaboration Terms ● $265m upfront payment for access to Regeneron’s research capabilities and technologies in IO ● Sanofi and Regeneron will invest over $1bn in R&D (split 75/25) ● Sanofi will re-allocate $75m to IO from existing collaboration(1) ● Sanofi opt-in rights at Proof of Concept ● After opt-in, partners share R&D costs and alternate development lead and U.S. commercialization(2) ● Worldwide profits shared 50/50 ● $375m upfront payment ● Sanofi and Regeneron will invest $650m in R&D (split 50/50) ● Worldwide profits shared 50/50 ● Regeneron leads development and consolidates U.S. sales ● Sanofi consolidates non-U.S. sales ● $375m milestone if sales of a PD-1 and any other collaboration antibody sold for use in combination with a PD-1 exceed $2bn over 12 months Exclusive IO antibody collaboration with Regeneron will last up to 8 years(3) IO: Immuno-Oncology (1) Sanofi to re-allocate $75m (over 3 years) to IO from its $160m annual contribution to existing collaboration (2) For antibodies that Regeneron leads development, development costs will be shared equally. For antibodies that Sanofi leads development, Sanofi will prefund and Regeneron will reimburse 50% of the costs through the IO collaboration development balance, in an annual amount equal to 10% of the Regeneron share of profits (3) Five years with an ability to extend the collaboration for selected ongoing programs for an additional three years
  • 26. Free Cash Flow Increased 29.0% in H1 2015 26 Net Debt (in €m) €363m Share Repurchase €1,243m€462m Proceeds from Issuance of Shares CapEx €667m Net Cash from Operating Activities Net Debt Dec 31, 2014 Net Debt Jun 30, 2015 €801m Dividend €3,694m Acquisitions, Licensing, Net of Disposals Other(1) (2) €7,171m €9,726m€3,751m (3) (1) FCF €3,084m FCF: Free Cash Flow (1) Including derivatives related to the financial debt +€302m at December 31st 2014 and +€305m at June 30th 2015 (2) Excluding Restructuring costs (3) Other including Restructuring costs and Fx impact
  • 27. Exclusivity Losses and Higher OpEx Expected in H2 2015 ● Slower sales growth of Venezuela and Merial ● Expected launch of insulin glargine biosimilar in Europe(1) and Japan ● Generic competition to Plavix® in Japan and Renagel® in Europe and possibly the U.S. ● Accelerating OpEx growth given: ● New R&D funding of Immuno-Oncology alliance, Toujeo® Phase IV program, dupilumab Phase III in Asthma ● Investment in Praluent® launch and Toujeo® DTC campaign 2727 H2 2015 (1) Already launched in two Eastern European markets
  • 28. Business EPS Growth Approximately +10%(3) Stable to slightly growing at CER(1,2) 28 (1) Barring major unforeseen adverse events (2) FY 2014 Business EPS of €5.20 (3) Difference between variation on a reported basis and variation at CER, when applying June 2015 average exchange rates to the remaining two quarters of the year Outlook for 2015 - Investing in Future Growth Drivers FY 2015 FX impact on Business EPS
  • 30. 30 Late Stage Pipeline – Pharma & Vaccines LixiLan lixisenatide + insulin glargine Fixed-Ratio / Type 2 diabetes patisiran (ALN-TTR02) siRNA inhibitor targeting TTR Familial amyloid polyneuropathy Clostridium difficile Toxoid vaccine Praluent® (alirocumab) Anti-PCSK9 mAb Hypercholesterolemia, EU SAR342434 insulin lispro Type 1+2 diabetes revusiran (ALN-TTRsc) siRNA inhibitor targeting TTR Familial amyloid cardiomyopathy Rotavirus Live attenuated tetravalent Rotavirus oral vaccine lixisenatide GLP-1 agonist Type 2 diabetes, U.S. sarilumab Anti-IL6R mAb Rheumatoid arthritis Kynamro® (mipomersen) Apolipoprotein B-100 antisense Severe HeFH, U.S. VaxiGrip® QIV IM Quadrivalent inactivated influenza vaccine Dengue Mild-to-severe dengue fever vaccine dupilumab Anti-IL4Rα mAb Atopic dermatitis, Asthma Jevtana® (cabazitaxel) Metastatic prostate cancer (1L) PR5i DTP-HepB-Polio-Hib Pediatric hexavalent vaccine, U.S., EU SYNVISC-ONE® Medical device Pain in hip OA 30 N N N N New Molecular Entity Immune Mediated Diseases Rare Diseases Oncology Diabetes Solutions Vaccines Infectious Diseases Cardiovascular / Renal Diseases Age Related Degenerative Diseases Ophthalmology Biosurgery Phase III Registration N N NN
  • 31. Early Stage Pipeline – Pharma & Vaccines dupilumab Anti-IL4Rα mAb Nasal polyposis; Eosinophilic oesophagitis isatuximab Anti-CD38 naked mAb Multiple myeloma Rabies VRVg Purified vero rabies vaccine vatelizumab Anti-VLA 2 mAb Multiple sclerosis SAR125844 C-MET kinase inhibitor NSCLC Meningitis ACYW conj. 2nd generation meningococcal conjugate infant vaccine SAR156597 IL4/IL13 Bi-specific mAb Idiopathic pulmonary fibrosis GZ402671 Oral GCS Inhibitor Fabry Disease Tuberculosis Recombinant subunit vaccine sarilumab Anti-IL6R mAb Uveitis olipudase alfa rhASM Niemann-Pick type B Combination ferroquine / OZ439 Antimalarial Phase II N N 31 N 31 N New Molecular Entity Immune Mediated Diseases Rare Diseases Oncology Diabetes Solutions Vaccines Infectious Diseases Cardiovascular / Renal Diseases Age Related Degenerative Diseases Ophthalmology Biosurgery N N N N
  • 32. Early Stage Pipeline – Pharma & Vaccines GZ402668 GLD52 (anti-CD52 mAb) Relapsing multiple sclerosis SAR566658 Maytansin-loaded anti-CA6 mAb Solid tumors GZ402666 neo GAA Pompe Disease Streptococcus pneumonia Meningitis & pneumonia vaccine SAR113244 Anti-CXCR5 mAb Systemic lupus erythematosus SAR408701 Anti-CEACAM5 ADC Solid tumors GZ389988 TRKA antagonist Osteoarthritis Herpes Simplex Virus Type 2 HSV-2 vaccine SAR228810 Anti-protofibrillar AB mAb Alzheimer’s disease REGN2810 PD-1 inhibitor Cancer StarGen® Gene therapy Stargardt disease SAR425899 GLP-1 / GCGR agonist Diabetes SAR125844 C-MET kinase inhibitor Solid tumors UshStat® Gene therapy Usher syndrome 1B SAR439152 Myosin inhibitor Hypertrophic cardiomyopathy Phase I N N N NN NN N 32 N New Molecular Entity Immune Mediated Diseases Rare Diseases Oncology Diabetes Solutions Vaccines Infectious Diseases Cardiovascular / Renal Diseases Age Related Degenerative Diseases Ophthalmology Biosurgery N N N N
  • 33. 33 Phase I Phase II Phase III Registration TOTAL Oncology 3 2 0 0 5 Diabetes Solutions 1 0 1 1 3 Cardiovascular / Renal Diseases 1 0 0 1 2 Immune Mediated Diseases 2 2 2 0 6 Infectious Diseases 0 1 0 0 1 Ophthalmology 2 0 0 0 2 Rare Diseases 2 2 2 0 6 Age Related Degenerative Diseases 1 0 0 0 1 Vaccines 2 3 3 2 10 TOTAL 14 10 8 4 R&D Pipeline Summary Table(1) 24 12 NMEs & Vaccines 36 33 26 (1) Excluding life cycle management programs
  • 34. 34 Expected R&D Milestones 34 Product Event Timing Praluent® (alirocumab) Expected EC regulatory decision in Hypercholesterolemia Q3 2015 LixiLan Expected Phase III top line results in Diabetes Q3 2015 Vaxigrip® QIV IM (3+ years) Expected EU regulatory submission Q4 2015 Dengue vaccine Expected regulatory decision in endemic countries Q4 2015 LixiLan Expected U.S. regulatory submission in Diabetes Q4 2015 sarilumab Expected U.S. regulatory submission in Rheumatoid Arthritis Q4 2015 PR5i vaccine (DTP-HepB-Polio-Hib) Expected U.S. regulatory decision Q4 2015 LixiLan Expected EU regulatory submission in Diabetes Q1 2016 PR5i vaccine (DTP-HepB-Polio-Hib) Expected EU regulatory decision Q1 2016 Meningitis ACYW conj. vaccine Expected start of Phase III trial Q1 2016 dupilumab Expected Phase III top line results in Atopic Dermatitis Q1 2016 Rotavirus vaccine Expected regulatory submission in India Q2 2016 insulin lispro Expected Phase III top line results in Diabetes Q2 2016
  • 36. Business EPS Currency Sensitivity Currency Exposure on Q2 2015 Sales Currency Average Rates 2015 Currency Sensitivity 36 Q2 2014 Q2 2015 % change EUR/USD 1.37 1.10 -19.7% EUR/JPY 140.03 134.14 -4.2% EUR/CNY 8.54 6.85 -19.8% EUR/RUB 47,96 58,12 +21.2% Currency Variation Business EPS Sensitivity U.S. Dollar -0.05 USD/EUR +EUR 0.10 Japanese Yen +5 JPY/EUR -EUR 0.03 Russian Ruble +10 RUB/EUR -EUR 0.06 € 23.0% US $ 35.6% Japanese Yen 5.5% Bristish £ 2.0% Australian $ 1.5% Canadian $ 1.5% Brazilian Real 3.2% Chinese Yuan 5.4% Russian Ruble 1.6% Others 19.3 % Mexican Peso 1.4%
  • 37. 37 Business Net Income Statement (1) Net of tax (2) Determined on the basis of Business income before tax, associates and non-controlling interests (3) Based on an average number of shares outstanding of 1,305.9 million in the second quarter of 2015 and 1,314.5 million in the second quarter of 2014 Second quarter 2015 Net sales 9,378 8,075 16.1% 7,800 6,820 14.4% 887 718 23.5% 691 537 28.7% - - Other revenues 83 71 16.9% 67 58 15.5% 8 7 14.3% 8 6 33.3% - - Cost of sales (2,938) (2,608) 12.7% (2,252) (2,058) 9.4% (450) (350) 28.6% (236) (200) 18.0% - - As % of net sales (31.3%) (32.3%) (28.9%) (30.2%) (50.7%) (48.8%) (34.2%) (37.2%) Gross profit 6,523 5,538 17.8% 5,615 4,820 16.5% 445 375 18.7% 463 343 35.0% - - As % of net sales 69.6% 68.6% 72.0% 70.7% 50.2% 52.2% 67.0% 63.9% Research & development expenses (1,290) (1,188) 8.6% (1,104) (1,030) 7.2% (142) (123) 15.4% (44) (35) 25.7% - - As % of net sales (13.8%) (14.7%) (14.2%) (15.1%) (16.0%) (17.1%) (6.4%) (6.5%) Selling and general expenses (2,648) (2,255) 17.4% (2,216) (1,930) 14.8% (188) (142) 32.4% (244) (183) 33.3% - - As % of net sales (28.2%) (27.9%) (28.4%) (28.3%) (21.2%) (19.8%) (35.3%) (34.1%) Other current operating income/expenses (20) 54 (11) 42 1 3 5 11 (15) (2) Share of profit/loss of associates(1) 30 26 29 25 1 1 - - - - Net income attributable to non-controlling interests (29) (30) (29) (30) - - - - - - Business operating income 2,566 2,145 19.6% 2,284 1,897 20.4% 117 114 2.6% 180 136 32.4% (15) (2) As % of net sales 27.4% 26.6% 29.3% 27.8% 13.2% 15.9% 26.0% 25.3% Financial income and expenses (112) (94) Income tax expense (614) (514) Tax rate (2) 25.0% 25.0% Business net income 1,840 1,537 19.7% As % of net sales 19.6% 19.0% Business earnings per share(3) (in euros) 1.41 1.17 20.5% OtherGroup Total Pharmaceuticals Vaccines Animal health change Q2 2015 Q2 2014change Q2 2015 Q2 2014 change Q2 2015 Q2 2014Q2 2014€ million Q2 2015 Q2 2014 change Q2 2015
  • 38. 38 Business Net Income Statement (1) Net of tax (2) Determined on the basis of Business income before tax, associates and non-controlling interests (3) Based on an average number of shares outstanding of 1,307.2 million in the first semester of 2015 and 1,317.2 million in the first semester of 2014 First Half 2015 Net sales 18,188 15,917 14.3% 15,255 13,517 12.9% 1,584 1,346 17.7% 1,349 1,054 28.0% Other revenues 163 154 5.8% 129 126 2.4% 14 14 - 20 14 42.9% - - Cost of sales (5,724) (5,124) 11.7% (4,442) (4,046) 9.8% (826) (700) 18.0% (456) (378) 20.6% - - As % of net sales (31.5%) (32.2%) (29.1%) (29.9%) (52.1%) (52.0%) (33.8%) (35.8%) Gross profit 12,627 10,947 15.3% 10,942 9,597 14.0% 772 660 17.0% 913 690 32.3% - - As % of net sales 69.4% 68.8% 71.7% 71.0% 48.7% 49.0% 67.7% 65.5% Research and development expenses (2,489) (2,327) 7.0% (2,143) (2,025) 5.8% (262) (230) 13.9% (84) (72) 16.7% - - As % of net sales (13.7%) (14.6%) (14.0%) (15.0%) (16.5%) (17.1%) (6.2%) (6.8%) Selling and general expenses (5,086) (4,333) 17.4% (4,310) (3,721) 15.8% (344) (271) 26.9% (432) (341) 26.7% - - As % of net sales (28.0%) (27.2%) (28.3%) (27.5%) (21.7%) (20.1%) (32.0%) (32.4%) Other current operating income/expenses (87) 29 (39) 19 2 1 5 17 (55) (8) Share of profit/loss of associates(1) 61 39 61 33 - 6 - - - - Net income attributable to non-controlling interests (62) (65) (62) (65) - - - - - - Business operating income 4,964 4,290 15.7% 4,449 3,838 15.9% 168 166 1.2% 402 294 36.7% (55) (8) As % of net sales 27.3% 27.0% 29.2% 28.4% 10.6% 12.3% 29.8% 27.9% Financial income and expenses (209) (170) Income tax expense (1,189) (1,036) Tax rate (2) 25.0% 25.0% Business net income 3,566 3,084 15.6% As % of net sales 19.6% 19.4% Business earnings per share(3) (in euros) 2.73 2.34 16.7% € million H1 2015 H1 2014 change H1 2015 Group Total Pharmaceuticals Vaccines Animal health H1 2014 H1 2015 H1 2014 Other H1 2014 change H1 2015 H1 2014H1 2015change change
  • 39. Reconciliation of Business Net Income to Consolidated Net Income Attributable to Equity Holders of Sanofi 39 (1) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €582 million in the second quarter of 2015 and €601 million in the second quarter of 2014 (2) Based on an average number of shares outstanding of 1,305.9 million in the second quarter of 2015 and 1,314.5 million in the second quarter of 2014 € million Q2 2015 Q2 2014 Change Business net income 1,840 1,537 19.7% Amortization of intangible assets(1) (611) (624) Impairment of intangible assets (1) (71) Fair value remeasurement of contingent consideration liabilities 70 (124) Restructuring costs (28) (84) Other gains and losses, and litigation - - Tax effect of: 206 274 amortization of intangible assets 214 207 impairment of intangible assets - 25 fair value remeasurement of contingent consideration liabilities (22) 13 other gains and losses, and litigation - - restructuring costs 14 29 Other tax items (111) (110) Share of items listed above attributable to non-controlling interests 2 3 Restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures (65) (24) Net income attributable to equity holders of Sanofi 1,302 777 67.6% Consolidated earnings per share(2) (in euros) 1.00 0.59
  • 40. Reconciliation of Business Net Income to Consolidated Net Income Attributable to Equity Holders of Sanofi 40 (1) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €1,172 million in the first semester of 2015 and €1,258 million in the first semester of 2014 (2) Day one profit on Alnylam shares presented in financial result (3) Tax on dividends paid to shareholders of Sanofi (4) Based on an average number of shares outstanding of 1,307.2 million in the first semester of 2015 and 1,317.2 million in the first semester of 2014 € million H1 2015 H1 2014 Change Business net income 3,566 3,084 15.6% Amortization of intangible assets(1) (1,229) (1,301) Impairment of intangible assets (28) (74) Fair value remeasurement of contingent consideration liabilities 71 (132) Restructuring costs (381) (135) Other gains and losses, and litigation(2) - 35 Tax effect of: 561 522 amortization of intangible assets 431 451 impairment of intangible assets 10 26 fair value remeasurement of contingent consideration liabilities (15) 14 other gains and losses, and litigation - (13) restructuring costs 135 44 Other tax items(3) (111) (110) Share of items listed above attributable to non-controlling interests 3 4 Restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures (127) (32) Net income attributable to equity holders of Sanofi 2,325 1,861 24.9% Consolidated earnings per share(4) (in euros) 1.78 1.41
  • 41. 41 Consolidated Income Statements (1) In 2015, including a tax on dividends paid to shareholders of Sanofi: (111)M€ compared to (110)M€ in 2014 € million Net sales 9,378 8,075 18,188 15,917 Other revenues 83 71 163 154 Cost of sales (2,938) (2,608) (5,724) (5,124) Gross profit 6,523 5,538 12,627 10,947 Research and development expenses (1,290) (1,188) (2,489) (2,327) Selling and general expenses (2,648) (2,255) (5,086) (4,333) Other operating income 47 106 83 116 Other operating expenses (67) (52) (170) (87) Amortization of intangible assets (611) (624) (1,229) (1,301) Impairment of intangible assets (1) (71) (28) (74) Fair value remeasurement of contingent consideration liabilities 70 (124) 71 (132) Restructuring costs (28) (84) (381) (135) Operating income 1,995 1,246 3,398 2,674 Financial expenses (134) (145) (267) (292) Financial income 22 51 58 157 Income before tax and associates and joint ventures 1,883 1,152 3,189 2,539 Income tax expense(1) (519) (350) (739) (624) Share of profit / loss of associates and joint ventures (35) 2 (66) 7 Net income 1,329 804 2,384 1,922 Net income attributable to non-controlling interests 27 27 59 61 Net income attributable to equity holders of Sanofi 1,302 777 2,325 1,861 Average number of shares outstanding (million) 1,305.9 1,314.5 1,307.2 1,317.2 Consolidated earnings per share (in euros) 1.00 0.59 1.78 1.41 Q2 2014Q2 2015 H1 2015 H1 2014
  • 42. 42 Cash Flow Statements (1) Excluding restructuring costs € million H1 2015 H1 2014 Business net income 3,566 3,084 Depreciation, amortization and impairment of property, plant and equipment and software 628 582 Gains and losses on disposals of non-current assets, net of tax (44) (97) Other non cash items (218) (98) Operating cash flow before changes in working capital(1) 3,932 3,471 Changes in working capital(1) (181) (552) Acquisitions of property, plant and equipment and software (667) (529) Free cash flow (1) 3,084 2,390 Acquisitions of intangible assets excluding software (280) (108) Acquisitions of investments in consolidated undertakings including assumed debt (169) (1,679) Restructuring costs (345) (382) Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of tax 86 179 Issuance of Sanofi shares 462 240 Dividends paid to shareholders of Sanofi (3,694) (3,676) Acquisition of treasury shares (1,243) (1,010) Disposals of treasury shares 1 - Transactions with non-controlling interests including dividends (16) (6) Foreign exchange impact (391) (37) Other items (50) (62) Change in net debt (2,555) (4,151)
  • 43. 43 Balance Sheets ASSETS € million June 30, 2015 Dec 31, 2014 LIABILITIES & EQUITY € million June 30, 2015 Dec 31, 2014 Property, plant and equipment 10,540 10,396 Equity attributable to equity holders of Sanofi 56,618 56,120 Intangible assets (including goodwill) 55,062 53,740 Equity attributable to non-controlling interests 156 148 Non-current financial assets & investments in associates and deferred tax assets 10,296 9,819 Total equity 56,774 56,268 Non-current assets 75,898 73,955 Long-term debt 10,770 13,276 Non-current liabilities related to business combinations and to non-controlling interests 1,132 1,133 Provisions and other non-current liabilities 9,206 9,578 Deferred tax liabilities 3,742 4,105 Non-current liabilities 24,850 28,092 Inventories, accounts receivable and other current assets 17,308 16,086 Accounts payable & Other current liabilities 12,192 11,363 Cash and cash equivalents 4,701 7,341 Current liabilities related to business combinations and to non-controlling interests 141 131 Current assets 22,009 23,427 Short-term debt and current portion of long-term debt 3,962 1,538 Current liabilities 16,295 13,032 Assets held for sale or exchange 16 10 Liabilities related to assets held for sale or exchange 4 - TOTAL ASSETS 97,923 97,392 TOTAL LIABILITIES & EQUITY 97,923 97,392